| Sumario: | <p>Cholinesterase inhibitors such as donepezil, galantamine and rivastigmine are drugs indicated for treatment of hypocholinergic dementias, particularly Alzheimer's disease. In clinical trials, cholinesterase inhibitors demonstrated beneficiai effect versus placebo on cognitive function, behavioral disturbances and global performance both to patients and carers. Cholinesterase inhibitors side effects are well known, widely discussed and primarily related to the cholinergic system. Nevertheless, so far, little attention has been paid to the use of cholinesterase inhibitors in patients with comorbidities. It is known that the typical patient in use of cholinesterase inhibitors is usually elderly or very elderly with associated comorbidities and receives treatment with multiple medications. The aim of this review article is to highlight the importance of performing a global clinical evaluation prior to the prescription of cholinesterase inhibitors to elderly patients with comorbidities so, rendering the prescription of these drugs safer in this particular group of patients.</p>
|
|---|
